Evidence for systems-level molecular mechanisms of tumorigenesis

Pilar Hernández1, Jaime Huerta-Cepas, David Montaner

  • 1Bioinformatics and Biostatistics Unit, and Translational Research Laboratory, Catalan Institute of Oncology, IDIBELL, L'Hospitalet, Barcelona, Spain. phgutierrez@ico.scs.es <phgutierrez@ico.scs.es>

BMC Genomics
|June 23, 2007
PubMed
Abstract

Insights

Cancer gene products (CGPs) are central to cellular networks, with down-regulated CGPs showing specific organization that promotes tumorigenesis. This molecular systems-level organization is key to malignant growth.

Area of Science:

  • Systems biology
  • Cancer research
  • Network biology

Background:

  • Cancer develops through accumulating genetic alterations.
  • These alterations reprogram molecular interactions within cellular networks.
  • Coordinated reprogramming enables malignant growth capabilities.

Purpose of the Study:

  • To investigate the coordinated function of cancer gene products (CGPs).
  • To define CGPs by their topological properties and organization in the interactome network.
  • To understand the role of CGPs in promoting tumorigenesis.

Main Methods:

  • Analysis of topological properties (degree, betweenness, closeness) of CGPs in the interactome network.
  • Identification of centrality measures for both up-regulated and down-regulated CGPs.
  • Correlation analysis of topological associations with biological processes.

Main Results:

  • Cancer gene products (CGPs) are central to information exchange in cellular networks.
  • Down-regulated CGPs systematically exhibit centrality and topological associations with tumorigenesis pathways.
  • Both up-regulated and down-regulated CGPs are crucial for overall network integrity.

Conclusions:

  • Tumorigenesis occurs via organized molecular systems-level changes.
  • A model of precise down-regulation of functionally-associated proteins, orchestrated with specific up-regulation, is proposed.
  • This organized molecular reprogramming drives malignant growth.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...